By Jennifer Ahlstrom | Posted - Aug 9th, 2017





Clinical Trial: Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

 Daratumumab is a newer immunotherapy approved by the FDA for relapsed myeloma. Because it has few side effects, many researchers want to see if it can be used in precursor stages of the disease to prevent it from progressing to active myeloma. 

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is Daratumumab.

The trial is open at the Dana Farber Cancer Institute, run by Dr. Irene Ghobrial, a myeloma specialist with a focus on precursor conditions. It is also open at Beth Israel Deaconess Medical Center in Boston.

To learn more about this trial and sign up to receive notifications, click here:  Study of the CD38 Antibody Daratumumab Clinical Trial

To find all eligible clinical trials, click here: 

Study of the CD38 Antibody Daratumumab Clinical Trial
Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.


Add a Comment



Thanks to our Myeloma Crowd Community sponsors:

.                         .       .